Literature DB >> 11849214

Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation.

Jen C Wang1, Wilson Chen, Selvarany Nallusamy, Chi Chen, Allan D Novetsky.   

Abstract

Hypermethylation of p15 and p16 genes was determined in 32 patients with agnogenic myeloid metaplasia(AMM), also known as idiopathic myelofibrosis (MF). These included 10 patients in leukaemic transformation phase. Using polymerase chain reaction-based methylation analysis assay methods, with substantiation using Southern blot analysis, the study showed no hypermethylation of p15 or p16 genes in the chronic phase of AMM, but p15 gene hypermethylation was found in four patients (40%) and p16 gene hypermethylation in two patients (20%) when they were in leukaemic transformation stage. Furthermore, two of the patients in leukaemic transformation were found to have both p15 and p16 gene hypermethylation, demonstrating possible multiple gene hypermethylation in the same patient. Thus, hypomethylation agents for treating patients with AMM in leukaemic transformation may be appropriate for future trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849214     DOI: 10.1046/j.0007-1048.2001.03319.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

3.  Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Authors:  Talha Badar; Hagop M Kantarjian; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Jorge E Cortes; Naveen Pemmaraju; Sherry R Pierce; Kate J Newberry; Naval Daver; Srdan Verstovsek
Journal:  Leuk Res       Date:  2015-06-11       Impact factor: 3.156

4.  Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Authors:  John Mascarenhas; Mark L Heaney; Vesna Najfeld; Elizabeth Hexner; Omar Abdel-Wahab; Raajit Rampal; Farhad Ravandi; Bruce Petersen; Gail Roboz; Eric Feldman; Nikolai Podoltsev; Dan Douer; Ross Levine; Martin Tallman; Ronald Hoffman
Journal:  Leuk Res       Date:  2012-08-28       Impact factor: 3.156

Review 5.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 6.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 7.  Pharmacotherapy of Myelofibrosis.

Authors:  Douglas Tremblay; Bridget Marcellino; John Mascarenhas
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 8.  Advances in myelofibrosis: a clinical case approach.

Authors:  John O Mascarenhas; Attilio Orazi; Kapil N Bhalla; Richard E Champlin; Claire Harrison; Ronald Hoffman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

9.  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  A Quintás-Cardama; W Tong; H Kantarjian; D Thomas; F Ravandi; S Kornblau; T Manshouri; J E Cortes; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

10.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; B Douglas Smith; Ivana Gojo; Steven D Gore; Mark J Levis; Hetty E Carraway; Jacqueline M Greer; S Percy Ivy; Keith W Pratz; Michael A McDevitt
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.